# All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

> **NCT06158412** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 25 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** All-trans Retinoic Acid in combination with the KPD Regimen

## Key facts

- **NCT ID:** NCT06158412
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-22
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158412, "All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06158412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*